17 research outputs found
Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond
Get PDFIn the past four decades, chemoprevention of colorectal cancer (CRC) has been the subject of many epidemiologic and intervention trials of naturally occurring or pharmacologic agents. Recently, the positioning of cyclooxygenase 2 inhibitors as a viable option in this context was a major breakthrough; however, it was hampered by adverse cardiovascular events. This review questions whether chemopreventive measures for CRC are ready to be used in mass or individual applications, standing alone or in combination with other CRC-preventive measures. It also discusses steps that may be undertaken to explore this field further
Serum ferritin in patients with inflammatory bowel disease (IBD) and in patients with giant cell arteritis (GCA)
No full textLong term course of markers of coagulation and fibrinolysis in relation to clinical disease activity in inflammatory bowel disease and in Giant cell arteritis
No full textS1207 Elevated Risk of Venous Thromboembolism in Patients With Inflammatory Bowel Disease: Results From a European Population-Based Cohort
No full textIs there a relation between quality of care and quality of life in IBD? The use of Quote-IBD in 127 patients
No full textMucosal capillary thrombi in steroid refractory ulcerative colitis: Influence of low molecular weight heparin (LMWH) treatment
No full textSerum Pro-inflammatory cytokines, gastrin and pepsinogens in screening for atrophic body gastritis
No full textMo1331 The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort
No full textS1201 Patient-Reported Utilization of Health Care Resources in Ulcerative Colitis and Crohn's Disease Matches Their Health Care Costs
No full text
